Company announcement,
The notification is based on the amendment to the Securities Market Act effective
% of shares and voting rights (total of 7.A) | % of shares and voting rights through financial instruments (total of 7.B) | Total of both in % (7.A + 7.B) | Total number of shares and voting rights of issuer | |
Resulting situation on the date on which threshold was crossed or reached | 8.28129 | 8.28129 | 6,764,562 | |
Positions of previous notification (if applicable) |
Notified details of the resulting situation on the date on which the threshold was crossed:
A: Shares and voting rights
Class/type of shares ISIN code (if possible) | Number of shares and voting rights | % of shares and voting rights | ||
Direct (SMA 9:5) | Indirect (SMA 9:6 ja 9:7) | Direct (SMA 9:5) | Indirect (SMA 9:6 ja 9:7) | |
FI4000506811 | 560,193 | 8.28129 | ||
SUBTOTAL A | 560,193 | 8.28129 |
Information in relation to the person subject to the notification obligation:
Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity:
% of shares and voting rights | % of shares and voting rights through financial instruments | Total of shares, voting rights, and financial instruments | |
Kyösti Kakkonen | 0 | 0 | 0 |
Kakkonen-Yhtiöt Oy | 0 | 0 | 0 |
Joensuun Kauppa ja | 6.41440 | 6.4144 | 433,906 |
1.866891 | 1.866891 | 126,287 |
Additional information: Kyösti Kakkonen holds 55.3 per cent of Kakkonen-Yhtiöt Oy, which holds 100 per cent of Joensuun Kauppa ja
Further information is available on the website www.nexstim.com, or by contacting:
+358 50 326 4101
mikko.karvinen@nexstim.com
The Company’s Certified Advisor is
About
Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS System 5 is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.
Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in
For more information, please visit www.nexstim.com
Attachment
- Nexstim Plc_Company Announcement_Liputusilmoitus_11062024_FINAL_EN
![](https://ml-eu.globenewswire.com/media/M2M3NjlkYzUtNzc4Zi00NjQzLWE3ZTctYzVjODExODZkMzg0LTEwMjc3Nzk=/tiny/Nexstim-Oyj.png)
© OMX, source